We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$495M
AUM Growth
-$74.9M
Cap. Flow
+$18.8M
Cap. Flow %
3.8%
Top 10 Hldgs %
58.78%
Holding
54
New
6
Increased
19
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$20.8M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$18.4M
3
ASND icon
Ascendis Pharma A/S
ASND
+$9.99M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$9.26M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$6.92M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$17.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$14.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$7.92M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$7.17M
5
BMY icon
Bristol-Myers Squibb
BMY
+$6.28M

Sector Composition

Rank Sector Weight
1 Healthcare 81.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
1
Acadia Pharmaceuticals
ACAD
$4.53B
$42.9M 8.66%
1,486,460
+693,961
+88% +$18.4M
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$34M 6.87%
9,263,340
+1,919,163
+26% +$5.68M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.9B
$33.1M 6.69%
400,000
-19,712
-5% -$1.7M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.09B
$31.4M 6.35%
4,520,643
+263,296
+6% +$1.81M
TSRO
5
DELISTED
TESARO, Inc.
TSRO
$31.2M 6.29%
231,700
-46,003
-17% -$5.8M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.66B
$27.7M 5.6%
1,010,300
-359,609
-26% -$14.4M
NDRM
7
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$23.4M 4.74%
1,056,303
+370,000
+54% +$6.92M
DERM
8
DELISTED
Dermira, Inc.
DERM
$23.2M 4.69%
765,709
-40,217
-5% -$1.3M
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
$23.1M 4.66%
610,000
+110,000
+22% +$4.16M
NBIX icon
10
Neurocrine Biosciences
NBIX
$18.3B
$20.9M 4.23%
541,000
+50,418
+10% +$2.28M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$20.8M 4.2%
+170,000
New +$20.8M
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
$20M 4.03%
4,017,577
+327,720
+9% +$2.27M
BMY icon
13
Bristol-Myers Squibb
BMY
$130B
$16.7M 3.36%
285,000
-114,875
-29% -$6.28M
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
$15.6M 3.15%
295,533
+154,033
+109% +$9.26M
AGEN
15
Agenus
AGEN
$286M
$15.5M 3.12%
191,084
+1,757
+0.9% +$173K
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$14.4M 2.91%
995,838
+126,575
+15% +$2.22M
ASND icon
17
Ascendis Pharma A/S
ASND
$16.6B
$11M 2.23%
545,203
+500,000
+1,106% +$9.99M
TLGT
18
DELISTED
Teligent, Inc
TLGT
$11M 2.22%
166,362
+2,580
+2% +$182K
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.46B
$10.3M 2.09%
1,631,502
+252,100
+18% +$1.31M
AKBA icon
20
Akebia Therapeutics
AKBA
$338M
$8.66M 1.75%
831,515
-113,064
-12% -$974K
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.16M 1.45%
1,508,201
+19,714
+1% +$107K
SRNE
22
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$7.13M 1.44%
1,456,056
-75,217
-5% -$452K
VCYT icon
23
Veracyte
VCYT
$4.51B
$7.02M 1.42%
906,999
-11,557
-1% -$86.4K
VNDA icon
24
Vanda Pharmaceuticals
VNDA
$299M
$6.08M 1.23%
381,466
-446,227
-54% -$7.17M
ALIM
25
DELISTED
Alimera Sciences
ALIM
$4.36M 0.88%
268,966
+30,633
+13% +$561K
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Avoro Capital Advisors held 54 positions worth $495M, down 13% from $570M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Avoro Capital Advisors deployed $18.8M of net new capital in Q4 2016, opening 6 new positions and adding to 19 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 170,000 shares worth $20.8M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $14.4M trimmed.

  • Avoro Capital Advisors's largest Q4 2016 buy was Alexion Pharmaceuticals: 170,000 shares worth $20.8M.
  • Avoro Capital Advisors added most to Acadia Pharmaceuticals in Q4 2016, an estimated $18.4M increase.
  • Avoro Capital Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $14.4M.
  • Avoro Capital Advisors fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2016, selling an estimated $17.7M.
  • Avoro Capital Advisors's ten largest holdings make up 59% of its $495M portfolio in Q4 2016.
  • Avoro Capital Advisors opened 6 new positions and closed 11 in Q4 2016.
  • Avoro Capital Advisors's portfolio value fell 13% quarter-over-quarter to $495M.

Based on Avoro Capital Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.